Coherus BioSciences Inc at JPMorgan Healthcare Conference Transcript
Good morning, everybody. I'm Chris Schott from JPMorgan and very happy to be introducing Coherus today. From Coherus, we have the company's President and CEO, Denny Lanfear.
With that, I'll turn it over to Denny.
Thank you, Chris. Let me first, of course, apprise you of the forward-looking statements and direct you to Coherus' various SEC filings, which address the various risks and so on with each of our products.
So today, I'm going to start talking about delivering on the promise of biosimilars. We founded this company, it'll be 10 years in September. And I think it's a good time, a year after launching UDENYCA, to take a step back and see how the biosimilar landscape has evolved. And I'm going to talk to you about the success of Coherus, particularly with UDENYCA, which we know, of course, was a breakthrough biosimilar product.
I'll go on and talk about our oncology
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
